PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
65.12 USD
-0.49 (-0.75%)
65.12 USD
0 (0%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
- PBH had positive earnings in the past year.
- In the past year PBH had a positive cash flow from operations.
- Of the past 5 years PBH 4 years were profitable.
- Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 5.83%, PBH belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
- With an excellent Return On Equity value of 11.00%, PBH belongs to the best of the industry, outperforming 85.94% of the companies in the same industry.
- The Return On Invested Capital of PBH (7.88%) is better than 85.94% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PBH is below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
- Looking at the Profit Margin, with a value of 18.09%, PBH belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
- In the last couple of years the Profit Margin of PBH has grown nicely.
- Looking at the Operating Margin, with a value of 31.00%, PBH belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
- In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
- PBH's Gross Margin of 56.10% is fine compared to the rest of the industry. PBH outperforms 68.23% of its industry peers.
- PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
- The number of shares outstanding for PBH has been reduced compared to 1 year ago.
- The number of shares outstanding for PBH has been reduced compared to 5 years ago.
- The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.61 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
- PBH has a Altman-Z score of 2.61. This is in the better half of the industry: PBH outperforms 63.54% of its industry peers.
- The Debt to FCF ratio of PBH is 3.97, which is a good value as it means it would take PBH, 3.97 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 3.97, PBH belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
- A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.61 |
ROIC/WACC0.89
WACC8.89%
2.3 Liquidity
- A Current Ratio of 3.70 indicates that PBH has no problem at all paying its short term obligations.
- PBH has a Current ratio of 3.70. This is comparable to the rest of the industry: PBH outperforms 57.29% of its industry peers.
- A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
- PBH's Quick ratio of 2.51 is in line compared to the rest of the industry. PBH outperforms 51.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 13.15% over the past year.
- PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
- PBH shows a decrease in Revenue. In the last year, the revenue decreased by -0.02%.
- The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
- Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.13% on average per year.
- PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 14.28, PBH is valued correctly.
- Based on the Price/Earnings ratio, PBH is valued cheaply inside the industry as 86.98% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.38. PBH is valued slightly cheaper when compared to this.
- PBH is valuated correctly with a Price/Forward Earnings ratio of 13.30.
- Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 84.38% of the companies in the same industry.
- PBH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.28 | ||
| Fwd PE | 13.3 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 86.98% of the companies in the same industry.
- 89.06% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.26 | ||
| EV/EBITDA | 10.77 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)8.7
PEG (5Y)1.61
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
- No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
65.12
-0.49 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-05 2026-02-05/bmo
Inst Owners108.83%
Inst Owner Change1.66%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.13B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (21.39%)
Short Float %4.5%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)0%
PT rev (3m)-7.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.28 | ||
| Fwd PE | 13.3 | ||
| P/S | 2.82 | ||
| P/FCF | 12.26 | ||
| P/OCF | 11.89 | ||
| P/B | 1.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.77 |
EPS(TTM)4.56
EY7%
EPS(NY)4.9
Fwd EY7.52%
FCF(TTM)5.31
FCFY8.16%
OCF(TTM)5.48
OCFY8.41%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.7
PEG (5Y)1.61
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.61 |
F-Score7
WACC8.89%
ROIC/WACC0.89
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.